MX356584B - Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica. - Google Patents

Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.

Info

Publication number
MX356584B
MX356584B MX2012009905A MX2012009905A MX356584B MX 356584 B MX356584 B MX 356584B MX 2012009905 A MX2012009905 A MX 2012009905A MX 2012009905 A MX2012009905 A MX 2012009905A MX 356584 B MX356584 B MX 356584B
Authority
MX
Mexico
Prior art keywords
treatment
mediated disease
inflammation mediated
metabolic inflammation
thiazolidinedione analogues
Prior art date
Application number
MX2012009905A
Other languages
English (en)
Inventor
F Kletzien Rolf
R Colca Gerard
Original Assignee
Metabolic Solutions Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Co filed Critical Metabolic Solutions Dev Co
Publication of MX356584B publication Critical patent/MX356584B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a análogos de tiazolidindiona que son útiles para el tratamiento de enfermedades mediadas por inflamación metabólica tal como diabetes.
MX2012009905A 2006-03-16 2007-03-14 Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica. MX356584B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78289406P 2006-03-16 2006-03-16
PCT/US2007/006321 WO2007109024A2 (en) 2006-03-16 2007-03-14 Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease

Publications (1)

Publication Number Publication Date
MX356584B true MX356584B (es) 2018-06-05

Family

ID=38328199

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012009905A MX356584B (es) 2006-03-16 2007-03-14 Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
MX2008011871A MX2008011871A (es) 2006-03-16 2007-03-14 Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2008011871A MX2008011871A (es) 2006-03-16 2007-03-14 Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.

Country Status (15)

Country Link
US (4) US20090143442A1 (es)
EP (3) EP2902026B1 (es)
JP (2) JP5269758B2 (es)
KR (1) KR101475955B1 (es)
CN (1) CN101454005B (es)
AU (1) AU2007227581B2 (es)
CA (1) CA2646207C (es)
ES (2) ES2654908T3 (es)
HU (1) HUE035314T2 (es)
MX (2) MX356584B (es)
NZ (1) NZ571871A (es)
PL (2) PL2902026T3 (es)
RU (1) RU2445957C2 (es)
UA (1) UA96441C2 (es)
WO (1) WO2007109024A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530293A (ja) * 2006-03-16 2009-08-27 メタボリック ソリューションズ ディベロップメント カンパニー チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法
EP2001469B1 (en) 2006-03-16 2012-05-23 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
NZ571871A (en) 2006-03-16 2011-07-29 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
EP2203433B1 (en) 2007-09-14 2012-10-31 Metabolic Solutions Development Company LLC 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
CN102177436B (zh) 2008-08-12 2015-05-13 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
JP2013514368A (ja) * 2009-12-15 2013-04-25 メタボリック ソリューションズ ディベロップメント カンパニー, エルエルシー 神経変性疾患を処置するための、ppar温存チアゾリジンジオンおよび組み合わせ物
MX2012006744A (es) * 2009-12-15 2012-07-30 Metabolic Solutions Dev Co Llc Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
AU2014202074B2 (en) * 2009-12-15 2016-01-07 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
US8912335B2 (en) * 2009-12-15 2014-12-16 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
GB2477743A (en) * 2010-02-10 2011-08-17 Argenta Therapeutics Ltd Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
MX2012012094A (es) * 2010-04-19 2012-12-17 Metabolic Solutions Dev Co Llc Sintesis novedosa para compuestos de tiazolidinadiona.
RU2012148908A (ru) 2010-04-19 2014-05-27 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Новый синтез соединений тиазолидиндиона
WO2012021467A1 (en) 2010-08-10 2012-02-16 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
RU2593370C2 (ru) 2010-08-10 2016-08-10 Октета Терапьютикс, ЭлЭлСи Новый способ синтеза соединений тиазолидиндиона
MX355479B (es) 2011-01-10 2018-04-19 Zinfandel Pharmaceuticals Inc Metodos y productos de farmaco para tratar enfermedad de alzheimer.
WO2012114204A2 (en) * 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
WO2012149083A1 (en) * 2011-04-28 2012-11-01 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
KR20130015932A (ko) * 2011-08-05 2013-02-14 연세대학교 산학협력단 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물
KR101501375B1 (ko) 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
WO2014046474A2 (ko) * 2012-09-21 2014-03-27 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
AU2013359903A1 (en) * 2012-12-11 2015-07-02 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
JP6800013B2 (ja) * 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムPoxel SA 重水素化2,4−チアゾリジンジオン及び治療方法
KR102349803B1 (ko) 2013-07-22 2022-01-12 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 대사 질환의 치료를 위한 ppar-절약 화합물
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
EA035866B1 (ru) * 2014-04-02 2020-08-21 Минорикс Терапьютикс С.Л. Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных
BR112019011334A2 (pt) 2016-12-01 2019-10-15 Minoryx Therapeutics S L uso de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona e seus sais
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
WO1985004170A1 (en) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1986002073A1 (en) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
KR100249988B1 (ko) * 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ATE376829T1 (de) * 1993-09-15 2007-11-15 Daiichi Sankyo Co Ltd Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NO318765B1 (no) 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
EE200300519A (et) 2001-04-26 2004-02-16 L�civa, a.s. Meetod pioglitasooni kui suhkurtõvevastase aine saamiseks
JPWO2005054213A1 (ja) * 2003-12-02 2007-12-06 塩野義製薬株式会社 ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
NZ571871A (en) 2006-03-16 2011-07-29 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
EP2001469B1 (en) 2006-03-16 2012-05-23 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
JP2009530293A (ja) * 2006-03-16 2009-08-27 メタボリック ソリューションズ ディベロップメント カンパニー チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法
EP2203433B1 (en) 2007-09-14 2012-10-31 Metabolic Solutions Development Company LLC 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes

Also Published As

Publication number Publication date
JP2013100371A (ja) 2013-05-23
EP2902026A1 (en) 2015-08-05
US8389556B2 (en) 2013-03-05
US20150190385A1 (en) 2015-07-09
PL2902026T3 (pl) 2018-03-30
ES2654908T8 (es) 2018-04-11
PL2001468T3 (pl) 2013-03-29
AU2007227581B2 (en) 2012-11-08
AU2007227581A1 (en) 2007-09-27
CN101454005B (zh) 2013-01-02
US20130203820A1 (en) 2013-08-08
HUE035314T2 (en) 2018-05-02
CN101454005A (zh) 2009-06-10
US9155729B2 (en) 2015-10-13
ES2654908T3 (es) 2018-02-15
JP5269758B2 (ja) 2013-08-21
KR20090037381A (ko) 2009-04-15
EP2486926A1 (en) 2012-08-15
WO2007109024A2 (en) 2007-09-27
ES2397944T3 (es) 2013-03-12
US20090143442A1 (en) 2009-06-04
EP2001468A2 (en) 2008-12-17
WO2007109024A3 (en) 2007-11-15
KR101475955B1 (ko) 2014-12-23
CA2646207A1 (en) 2007-09-27
EP2001468B1 (en) 2012-10-31
UA96441C2 (ru) 2011-11-10
NZ571871A (en) 2011-07-29
EP2902026B1 (en) 2017-10-04
JP2009530283A (ja) 2009-08-27
CA2646207C (en) 2016-01-19
RU2445957C2 (ru) 2012-03-27
RU2008140943A (ru) 2010-04-27
MX2008011871A (es) 2009-02-10
US20120015982A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
MX356584B (es) Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
MX2012006730A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas.
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX364200B (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
TN2011000201A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase - iv inhibitors for the treatment or prevention of diabetes
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001639A1 (ru) Композиции и способы их получения и применения
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MX2012004525A (es) Compuestos.
IN2012DN00971A (es)
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
MX2011009493A (es) Compuestos para el tratamiento de trastornos metabolicos.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
MX2008011872A (es) Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.